{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:48:36Z","timestamp":1777110516688,"version":"3.51.4"},"reference-count":41,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,5,15]],"date-time":"2002-05-15T00:00:00Z","timestamp":1021420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Industrial Med"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>A beryllium materials manufacturer is conducting a limited pilot program that offers testing for HLA\u2010DP\u03b21<jats:sup>E69<\/jats:sup> with genetic counseling through a third party to applicants for employment. An important consideration in this regard is the prevalence of this marker in the general population, and its consequent positive predictive value of disease susceptibility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Polymerase chain reaction and restriction fragment length polymorphism analyses were used to determine HLA\u2010DP\u03b21<jats:sup>E69<\/jats:sup> population frequencies. Estimation of positive predictive values assumed a disease frequency among beryllium workers of either 5 or 15% and used an odds ratio for disease risk of 35 for the HLA\u2010DP\u03b21<jats:sup>E69<\/jats:sup> marker.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Allelic\/carrier frequencies were found to be 0.21\/0.33, 0.24\/0.40, 0.27\/0.47, and 0.38\/0.59 for Caucasians, African\u2010Americans, Hispanics, and Chinese, respectively. Ranges of positive predictive values for a genetic test based on HLA\u2010DP\u03b21<jats:sup>E69<\/jats:sup> in these populations were calculated to be 8.3\u201314.3% for carriers with an assumed disease frequency of 5%. For high risk subgroups with disease frequencies of 15%, the range of positive predictive values was found to span between 24.9\u201343.0%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These estimates suggest that using HLA\u2010DP\u03b21<jats:sup>E69<\/jats:sup> genotyping for general pre\u2010employment screening in the beryllium industry has a low positive predictive value, which varies little among racial groups where carrier frequencies differ significantly. Am. J. Ind. Med. 41:457\u2013465, 2002. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ajim.10072","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T23:48:25Z","timestamp":1030319305000},"page":"457-465","source":"Crossref","is-referenced-by-count":15,"title":["Racial differences in prevalence of a supratypic HLA\u2010genetic marker immaterial to pre\u2010employment testing for susceptibility to chronic beryllium disease"],"prefix":"10.1002","volume":"41","author":[{"given":"Ainsley","family":"Weston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Ensey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Kreiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Channa","family":"Keshava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"McCanlies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,5,15]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0198-8859(91)90100-N"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/0272-4332.00009"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.2.210"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.2307\/3434755"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7089567"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.75.10.1204"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/oso\/9780195052886.003.0010","volume-title":"Fundamentals of genetic epidemiology\u2014Monographs in epidemiology and biostatistics","author":"Khoury MJ","year":"1993"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0274(199607)30:1<16::AID-AJIM3>3.0.CO;2-Q"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.94102526"},{"key":"e_1_2_1_11_1","first-page":"27","article-title":"Frequencies of HLA\u2010DRB1, \u2010DQB1 and \u2010DPB1 alleles in Czech population","volume":"45","author":"Loudova M","year":"1999","journal-title":"Folia Biologica"},{"key":"e_1_2_1_12_1","unstructured":"LuiZ LinJ ChenW JiaZ PanD XuA.2001.Sequence of complete exon 2 and partial intron 2 of HLA\u2010DPB1*8001 allele. (GenBank accession # AF336231)."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.2000.00765.x"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1992.tb01961.x"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1998.tb03016.x"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2000.560615.x"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1998.tb03033.x"},{"key":"e_1_2_1_18_1","first-page":"661","article-title":"The nucleotide sequence of two new DP alleles, DPA1*02015 and DPB1*8401, identified in a Chinese subject","volume":"17","author":"McTernan CL","year":"2000","journal-title":"Tissue Antigens"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1992.tb02109.x"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8105535"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(99)00103-5"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2370.1998.00114.x"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(99)00032-4"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1054\/tuld.1999.0213"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8105536"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0274(199710)32:4<337::AID-AJIM3>3.0.CO;2-R"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2000.560313.x"},{"key":"e_1_2_1_28_1","first-page":"707","volume-title":"Genetics","author":"Russell PJ","year":"1992"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.01.00106201"},{"key":"e_1_2_1_30_1","volume-title":"User's Guide: Statistics, Version 7\u20101","author":"SAS Institute","year":"1999"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.1999.530213.x"},{"key":"e_1_2_1_32_1","first-page":"564","article-title":"Hyper\u2010susceptibility and genetic problems in occupational medicine\u2014a consensus report","volume":"15","author":"Stokinger HE","year":"1972","journal-title":"J Occup Med"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2000.550216.x"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2000.560613.x"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0198-8859(92)90063-S"},{"key":"e_1_2_1_36_1","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.4049\/jimmunol.163.3.1647","article-title":"Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA\u2010DPB1 and \u2010DPA1 alleles","volume":"163","author":"Wang Z","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-483X(01)00410-3"},{"key":"e_1_2_1_38_1","first-page":"105","article-title":"p53 haplotype determination in breast cancer","volume":"6","author":"Weston A","year":"1997","journal-title":"Cancer Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(61)90121-8"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1006\/enrs.2000.4075"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105033441811"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/00028896209343198"}],"container-title":["American Journal of Industrial Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajim.10072","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajim.10072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T12:47:08Z","timestamp":1700398028000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajim.10072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,15]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1002\/ajim.10072"],"URL":"https:\/\/doi.org\/10.1002\/ajim.10072","archive":["Portico"],"relation":{},"ISSN":["0271-3586","1097-0274"],"issn-type":[{"value":"0271-3586","type":"print"},{"value":"1097-0274","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,15]]}}}